Spotlight Pathology has secured a £1.4 million seed investment to further develop its AI-powered tools accelerating the diagnosis of blood cancers and move them towards clinical adoption.

The round was co-led by the UK Innovation and Science Seed Fund (UKI2S) and Liverpool City Region Seed Fund, managed by AXM Venture Capital, with participation from River Capital, alongside follow-on investment from existing backers Deepbridge, EHE Ventures, Lyva Labs and Deepbridge.

The company is based at UKRI’s Daresbury Laboratory campus in the Liverpool City Region.